Lorus Therapeutics Inc – Product Pipeline Review – Q1 2011 by GlobalMarketsDirect

VIEWS: 0 PAGES: 59

More Info
									    Lorus Therapeutics Inc – Product Pipeline Review –
                         Q1 2011
                                                                                          Reference Code: GMDHC1181CDB

                                                                                                Publication Date: MAY 2011




Lorus Therapeutics Inc – Product Pipeline Review – Q1 2011                                  GMDHC1181CDB / Published MAY 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                Page(1)
Lorus Therapeutics Inc – Product Pipeline Review




Ta b le o f Co n te n t
Table of Content                                                                                                      2
List of Tables                                                                                                        4
List of Figures                                                                                                       5
Lorus Therapeutics Inc Snapshot                                                                                       6
    Lorus Therapeutics Inc Overview                                                                                   6
    Key Information                                                                                                   6
    Key Facts                                                                                                         6
Lorus Therapeutics Inc – Research and Development Overview                                                            7
    Key Therapeutic Areas                                                                                             7
Lorus Therapeutics Inc – Pipeline Review                                                                             10
    Pipeline Products by Stage of Development                                                                        10
    Pipeline Products – Monotherapy                                                                                  11
    Pipeline Products – Combination Treatment Modalities                                                             12
Lorus Therapeutics Inc – Pipeline Products Glance                                                                    13
    Lorus Therapeutics Inc Clinical Stage Pipeline Products                                                          13
         Phase II Products/Combination Treatment Modalities                                                          13
         Phase I Products/Combination Treatment Modalities                                                           14
    Lorus Therapeutics Inc–Early Stage Pipeline Products                                                             15
         Pre-Clinical Products/Combination Treatment Modalities                                                      15
         Discovery Products/Combination Treatment Modalities                                                         16
Lorus Therapeutics Inc – Drug Profiles                                                                               17
    GTI 2040 + Cytarabine                                                                                            17
         Product Description                                                                                         17
         Mechanism of Action                                                                                         17
         R&D Progress                                                                                                17
    LOR-2040                                                                                                         18
         Product Description                                                                                         18
         Mechanism of Action                                                                                         18
         R&D Progress                                                                                                18
    LOR-2040 + Cytarabine                                                                                            20
         Product Description                                                                                         20
         Mechanism of Action                                                                                         20
         R&D Progress                                                                                                20
    Virulizin                                                                                                        21
         Product Description                                                                                         21
         Mechanism of Action                                                                                         21
         R&D Progress                                                                                                21
    LOR-253                                                                                                          22
         Product Description                                                                                         22
         Mechanism of Action                                                                                         22
         R&D Progress                                                                                                22
    IL-17E                                                                                                           23
         Product Description                                                                                         23
         Mechanism of Action                                                                                         23
         R&D Progress                                                                                                23
    LOR-1284                                                                                                         24




Lorus Therapeutics Inc – Product Pipeline Review – Q1 2011                                GMDHC1181CDB / Published MAY 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(2)
Lorus Therapeutics Inc – Product Pipeline Review



         Product Description                                                                                                      24
         Mechanism of Action                                                                                                      24
         R&D Progress                                                                                                             24
    LOR-220                                                                                                                       25
         Product Description                                                                                                      25
         Mechanism of Action                                                                                                      25
         R&D Progress                                                                                                             25
    LOR-253                                                                                                                       26
         Product Description                                                                                                      26
         Mechanism of Action                                                                                                      26
         R&D Progress                                                                                                             26
    LOR-264                                                                                                                       27
         Product Description                                                                                                      27
         Mechanism of Action                                                                                                      27
         R&D Progress                                                                                                             27
    LOR-500                                                                                                                       28
         Product Description                                                                                                      28
         Mechanism of Action                                                                                                      28
         R&D Progress                                                                                                             28
Lorus Therapeutics Inc – Pipeline Analysis                                                                                        29
    Lorus Therapeutics Inc – Pipeline Products by Therapeutic Class                                                               29
    Lorus Therapeutics Inc - Pipeline Products By Target                                                                          31
    Lorus Therapeutics Inc – Pipeline Products by Route of Administration                                                         32
    Lorus Therapeutics Inc – Pipeline Products by Molecule Type                                                                   33
Lorus Therapeutics Inc – Recent Pipeline Updates                                                                                  34
Lorus Therapeutics Inc - Dormant Projects                                                                                         36
Lorus Therapeutics Inc - Discontinued Pipeline Products                                                                           37
    Discontinued Pipeline Product Profiles                                                                                        37
         Virulizin + Gemcitabine                                                                                                  37
Lorus Therapeutics Inc – Company Statement                                                                                        38
Lorus Therapeutics Inc – Locations And Subsidiaries                                                                               40
    Head Office                                                                                                                   40
    Other Locations & Subsidiaries                                                                                                40
Financial Deals Landscape                                                                                                         41
    Lorus Therapeutics Inc, Deals Volume Summary, 2004 to YTD 2011                                                                41
    Lorus Therapeutics Inc, Deals Summary By Region, 2004 to YTD 2011                                                             42
    Lorus Therapeutics Inc, Deals Summary, 2004 to YTD 2011                                                                       43
    Lorus Therapeutics Inc Detailed Deal Summary                                                                                  44
         Equity Offering                                                                                                          44
         Lorus Therapeutics Completes Private Placement Of $2 Million                                                             44
         Lorus Therapeutics Completes Rights Offering Of $3.63 Million                                                            46
         Lorus Therapeutics Completes Private Placement Of $1.6 Million                                                           48
         Lorus Therapeutics Completes Private Placement Of $9.22 Million                                                          50
         Debt Offering                                                                                                            52
         Lorus Therapeutics Completes Private Placement Of Convertible Debentures For $11.96 Million                              52
         Lorus Therapeutics Extends Co-Operative Research Agreement With NCI                                                      53
         Lorus Therapeutics Enters Into A Research Agreement With Dr. Guido Marcucci                                              54
         Lorus Therapeutics Enters Into An Agreement With Sumitomo and Koken                                                      55




Lorus Therapeutics Inc – Product Pipeline Review – Q1 2011                                             GMDHC1181CDB / Published MAY 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                          Page(3)
Lorus Therapeutics Inc – Product Pipeline Review



         Licensing Agreements                                                                                        56
         Lorus Therapeutics Extends Agreement With Zor Pharmaceuticals                                               56
         Lorus Therapeutics Enters Into Licensing Agreement With Zor Pharmaceuticals                                 57
Appendix                                                                                                             58
    Methodology                                                                                                      58
         Coverage                                                                                                    58
         Secondary Research                                                                                          58
         Primary Research                                                                                            58
         Expert Panel Validation                                                                                     59
    Contact Us                                                                                                       59
    Disclaimer                         
								
To top